J. Goldman & Co’s TherapeuticsMD TXMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-13,562
| Closed | -$14.6K | – | 747 |
|
|
2025
Q3 | $14.6K | Hold |
13,562
| – | – | ﹤0.01% | 438 |
|
|
2025
Q2 | $15.7K | Hold |
13,562
| – | – | ﹤0.01% | 435 |
|
|
2025
Q1 | $12.5K | Hold |
13,562
| – | – | ﹤0.01% | 459 |
|
|
2024
Q4 | $11.7K | Hold |
13,562
| – | – | ﹤0.01% | 433 |
|
|
2024
Q3 | $22.5K | Hold |
13,562
| – | – | ﹤0.01% | 438 |
|
|
2024
Q2 | $21.8K | Hold |
13,562
| – | – | ﹤0.01% | 424 |
|
|
2024
Q1 | $31.1K | Hold |
13,562
| – | – | ﹤0.01% | 397 |
|
|
2023
Q4 | $30.5K | Hold |
13,562
| – | – | ﹤0.01% | 319 |
|
|
2023
Q3 | $41K | Hold |
13,562
| – | – | ﹤0.01% | 338 |
|
|
2023
Q2 | $55.9K | Hold |
13,562
| – | – | ﹤0.01% | 354 |
|
|
2023
Q1 | $50.9K | Hold |
13,562
| – | – | ﹤0.01% | 334 |
|
|
2022
Q4 | $75.8K | Sell |
13,562
-69,414
| -84% | -$409K | ﹤0.01% | 328 |
|
|
2022
Q3 | $551K | Buy |
+82,976
| New | +$672K | 0.03% | 290 |
|
|
2021
Q1 | – | Sell |
-1,385
| Closed | -$84K | – | 533 |
|
|
2020
Q4 | $84K | Sell |
1,385
-1,556
| -53% | -$106K | ﹤0.01% | 345 |
|
|
2020
Q3 | $232K | Sell |
2,941
-2,173
| -42% | -$173K | 0.02% | 279 |
|
|
2020
Q2 | $320K | Sell |
5,114
-17,140
| -77% | -$998K | 0.02% | 235 |
|
|
2020
Q1 | $1.18M | Sell |
22,254
-27,436
| -55% | -$2.72M | 0.14% | 132 |
|
|
2019
Q4 | $6.01M | Buy |
49,690
+36,801
| +286% | +$5.29M | 0.43% | 65 |
|
|
2019
Q3 | $2.34M | Sell |
12,889
-20,847
| -62% | -$2.94M | 0.18% | 143 |
|
|
2019
Q2 | $4.39M | Sell |
33,736
-5,915
| -15% | -$1.06M | 0.3% | 106 |
|
|
2019
Q1 | $9.65M | Buy |
39,651
+6,870
| +21% | +$1.82M | 0.54% | 52 |
|
|
2018
Q4 | $6.25M | Buy |
32,781
+31,765
| +3,126% | +$7.75M | 0.48% | 56 |
|
|
2018
Q3 | $333K | Sell |
1,016
-3,677
| -78% | -$1.13M | 0.02% | 235 |
|
|
2018
Q2 | $1.46M | Sell |
4,693
-10,269
| -69% | -$3.14M | 0.08% | 232 |
|
|
2018
Q1 | $3.64M | Buy |
14,962
+3,214
| +27% | +$902K | 0.16% | 157 |
|
|
2017
Q4 | $3.55M | Sell |
11,748
-4,542
| -28% | -$1.26M | 0.19% | 141 |
|
|
2017
Q3 | $4.31M | Buy |
16,290
+3,642
| +29% | +$1.05M | 0.22% | 124 |
|
|
2017
Q2 | $3.33M | Buy |
12,648
+10,406
| +464% | +$2.61M | 0.18% | 138 |
|
|
2017
Q1 | $807K | Sell |
2,242
-10,825
| -83% | -$3.35M | 0.04% | 263 |
|
|
2016
Q4 | $3.77M | Sell |
13,067
-981
| -7% | -$304K | 0.25% | 124 |
|
|
2016
Q3 | $4.78M | Buy |
+14,048
| New | +$5.13M | 0.27% | 109 |
|
|
2015
Q4 | – | Sell |
-4,837
| Closed | -$1.42M | – | 302 |
|
|
2015
Q3 | $1.42M | Buy |
+4,837
| New | +$1.72M | 0.12% | 158 |
|
Other funds holding TXMD
RCMNY
CC
TC
ACM
J. Goldman & Co's TXMD Position: Q4 2025 in Review
J. Goldman & Co sold out of TherapeuticsMD (TXMD) in Q4 2025, closing a stake of 13,562 shares — an estimated $14.6K sold.
J. Goldman & Co first reported a position in TXMD in Q3 2015 and held it in 32 quarters. The position peaked at $9.65M in Q1 2019. 44 funds tracked by Wall St. Rank hold TXMD as of Q4 2025.
- J. Goldman & Co reported no remaining TherapeuticsMD position as of Q4 2025 after selling out during the quarter.
- J. Goldman & Co sold 13,562 TherapeuticsMD shares in Q4 2025, an estimated $14.6K.
- J. Goldman & Co first reported a position in TherapeuticsMD in Q3 2015 and held it in 32 quarters.
- J. Goldman & Co's TherapeuticsMD position peaked at $9.65M in Q1 2019.
- 44 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2025.
Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.